Inter Parfums to partner with Betsey Johnson
This article was originally published in The Rose Sheet
Executive Summary
New York-based firm has entered into a global agreement with fashion designer Betsey Johnson to design, manufacture and sell fragrance, color cosmetics and other personal-care products through Betsey Johnson stores, in addition to licensing products for sale at specialty stores, department stores and other retail outlets. Inter Parfums "envison[s] building an upscale fragrance and beauty enterprise around the qualities that have defined and redefined the Betsey Johnson label," President Andy Clarke states in July 9 release. First product launch is expected in August "with a new take on the designer's vintage fragrance," firm says
You may also be interested in...
Inter Parfums posts preliminary Q2 numbers
Inter Parfums announced July 23 that net sales for the second quarter of 2010 jumped to $107.8 million, a 21.6% increase from the same period last year. Fragrance brands leading the charge are Lanvin, with a 21% increase in sales, Burberry, up 26%, and Paul Smith, up 12%. New releases from Van Cleef & Arpels drove the brand's sales up 36%, while S.T. Dupont's two new entries, Intense and Essence Pure Ice, headed a 65% sales gain. By region, first-half sales rose 68% in Eastern Europe and 67% in South America. North America enjoyed a more modest increase of 14%, and Europe, 12%. Inter Parfums will release its final results for the second quarter Aug. 9. Earlier this month, the firm inked a licensing arrangement with designer Betsey Johnson to design, manufacture and sell fragrance, color cosmetics and other personal-care products thorough Betsey Johnson stores (1"The Rose Sheet" July 12, 2010, In Brief)
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.